Delivery Order SPE2DB22D2006-SPE2DB25FW3PR
- Not listed
- The Defense Logistics Agency awarded a delivery order valued at $2,969.84 to AmerisourceBergen Drug Corp for Telmisartan-HCTZ 80-25 mg tablets in unit dose packaging (30-count). This firm fixed price delivery order was competitively awarded without set-aside designation and is scheduled for completion by August 12, 2025. The contract is being performed at AmerisourceBergen's corporate office location in Conshohocken, Pennsylvania. This delivery order represents a single transaction under...
- The Defense Logistics Agency awarded a delivery order valued at $5,083.49 to AmerisourceBergen Drug Corp for the supply of Telmisartan-HCTZ 80-12.5 mg tablets in unit dose packaging (30 count) under a firm fixed price contract. This delivery order, which was competitively awarded with no set-aside designation, was executed on July 23, 2025, with an ultimate completion date of July 24, 2025. Performance will take place at the contractor's Corporate Office location in Conshohocken, Pennsylvania....
- The Defense Logistics Agency awarded a delivery order valued at $2,833.03 to AmerisourceBergen Drug Corp for the supply of Telmisartan-HCTZ 40-12.5 mg tablets in unit dose packaging (30-count) on August 1, 2025, with an ultimate completion date of August 4, 2025. This is a firm fixed price, non-set-aside contract performed at AmerisourceBergen's corporate office location in Conshohocken, Pennsylvania. The delivery order represents a child contract under AmerisourceBergen's larger Indefinite...
- The Defense Logistics Agency awarded a delivery order valued at $1,969.51 to AmerisourceBergen Drug Corp for the supply of Telmisartan-HCTZ 80-12.5 mg tablets in unit dose packaging (30 count) with an ultimate completion date of August 14, 2025. This competitively awarded, firm fixed-price delivery order carries no set-aside designation and will be performed at the contractor's facility in Conshohocken, Pennsylvania. The contract represents a routine pharmaceutical procurement supporting federal...
- The U.S. Defense Logistics Agency (DLA) awarded a firm-fixed-price delivery order contract worth $16,557.69 to AmerisourceBergen Drug Corp, a subsidiary of AmerisourceBergen Corporation, to provide Telmisartan-HCTZ 80-25 mg tablets in 30-count packages. The contract has a performance period through March 18, 2024. This delivery order is part of a larger indefinite delivery contract (IDC) awarded by DLA to AmerisourceBergen Drug Corp with a potential value of $999,999,999.00 and a performance...
- The Defense Logistics Agency awarded a $14,672.56 delivery order to AmerisourceBergen Drug Corp on July 24, 2025, for the supply of Telmisartan-HCTZ 40-12.5 mg tablets in unit dose packaging (30-count). The contract is structured as a firm fixed price delivery order with a completion date of July 25, 2025, and will be performed at the vendor's corporate office location in Conshohocken, Pennsylvania. No set-aside designation was applied to this competitively awarded contract. This delivery...
- The Defense Logistics Agency awarded a delivery order valued at $3,007.04 to AmerisourceBergen Drug Corp for Telmisartan-HCTZ 40-12.5 mg tablets in unit dose packages of 30 units. This competitive award, issued on July 22, 2025, with an ultimate completion date of July 23, 2025, utilizes firm fixed pricing and represents a child contract under AmerisourceBergen's larger Indefinite Delivery Contract with DLA Troop Support Medical. The pharmaceutical product will be delivered to the company's...
- The Defense Logistics Agency (DLA) awarded AmerisourceBergen Drug Corp a delivery order valued at $1,151.04 for Telmisartan-HCTZ 80-25 mg tablet unit dose packages (30 count) with an ultimate completion date of August 1, 2025. This firm fixed price delivery order was competitively awarded with no set-aside designation and will be performed at the awardee's facility in Conshohocken, Pennsylvania. The contract covers the supply of this antihypertensive pharmaceutical product to support federal...
- The Defense Logistics Agency awarded a delivery order to AmerisourceBergen Drug Corp on August 12, 2025, for the supply of Telmisartan-HCTZ 80-25 mg tablets in unit dose packaging (30-count). This competitively awarded, non-set-aside contract carries a ceiling value of $4,574.72 and is structured as a firm fixed-price delivery order with an ultimate completion date of August 13, 2025. The place of performance is AmerisourceBergen's corporate office location in Conshohocken, Pennsylvania. This...
- AmerisourceBergen Drug Corp, a major pharmaceutical distributor headquartered in Conshohocken, Pennsylvania, has been awarded a delivery order by the Defense Logistics Agency (DLA) for the supply of Telmisartan-HCTZ 40-12.5 mg tablets in unit dose packaging (30-count). Valued at $1,463.52 with a firm fixed price structure, this non-set-aside competitive award was executed on July 29, 2025, with an ultimate completion date of July 30, 2025. The contract is issued as a child delivery order under...
- SPE2DB22D2006Indefinite Delivery Contract
- SPE2DB22D2006-SPE2DB25FW3PRDelivery Order
The Defense Logistics Agency awarded a delivery order valued at $19,104.00 to AmerisourceBergen Drug Corp for the supply of Telmisartan-HCTZ 40-12.5 mg tablets in unit dose packaging (30 count) under a firm fixed-price contract. The award was made on August 15, 2025, with an ultimate completion date of August 18, 2025, and represents a non-set-aside competitive award. The product will be delivered to AmerisourceBergen's facility in Conshohocken, Pennsylvania, where the company maintains its corporate headquarters and serves as a major pharmaceutical distributor for federal medical procurement. This delivery order is issued under AmerisourceBergen's existing Indefinite Delivery Contract (IDC) with DLA Troop Support Medical, a $999.999 billion comprehensive pharmaceutical support vehicle running through December 2026. The prime contract serves military and federal healthcare systems globally, enabling the contractor to supply a broad range of pharmaceutical products, medical devices, and healthcare commodities across multiple therapeutic domains. Telmisartan-HCTZ, an antihypertensive combination medication, falls within the scope of pharmaceutical products covered under this strategic contract vehicle designed to support Defense Health Agency operations and other government healthcare systems.
Mod # | Description | ReasonForModification | Federal Obligation | Date |
|---|---|---|---|---|
| Not listed | Not listed | $19.1k | 8/15/25 |